Source: Virtual Congress 2021 – ALERT: COPD



Rating:

Share or cite this content

Citations should be made in the following way:
A. Yousuf (Leicester, United Kingdom), S. Mohammed (Leicester, United Kingdom), L. Carr (Leicester, United Kingdom), M. Yavari Ramsheh (Leicester, United Kingdom), K. Haldar (Leicester, United Kingdom), A. Wright (Leicester, United Kingdom), P. Novotny (Leicester, United Kingdom), S. Parker (Leicester, United Kingdom), S. Glover (Leicester, United Kingdom), J. Finch (Leicester, United Kingdom), K. Hadley (Leicester, United Kingdom), N. Quann (Leicester, United Kingdom), C. Micieli (Leicester, United Kingdom), V. Mistry (Leicester, United Kingdom), C. Brookes (Leicester, United Kingdom), R. Hobson (Leicester, United Kingdom), W. Ibrahim (Leicester, United Kingdom), R. Russell (Leicester, United Kingdom), D. Choy (San Francisco, United States of America), D. Cheung (San Francisco, United States of America), M. Grimbaldeston (San Francisco, United States of America), C. John (Leicester, United Kingdom), M. Steiner (Leicester, United Kingdom), N. Greening (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom). Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial. 206

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Short term glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: "REDUCE*", a non-inferiority multicenter trial. (*Reduction in the Use of Corticosteroids in Exacerbated COPD; ISRCTN19646069) Source: Annual Congress 2012 - Acute exacerbation in COPD Year: 2012 LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Heliox and alveolar oxygenation in patients with chronic obstructive pulmonary disease: a multicentre, randomised, crossover study Source: Eur Respir J 2004; 24: Suppl. 48, 243s Year: 2004 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Interval exercise for patients with severe COPD – randomised trial [SRCTN11611768] Source: Annual Congress 2006 - Organisation and programmes in pulmonary rehabilitation Year: 2006 Late Breaking Abstract - Frequency Pulmonary embolism (PE) in patients with an acute Exacerbation of chronic obstructive Pulmonary disease (COPD). PEP prospective trial. Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Late-breaking abstract: Sildenafil for chronic obstructive pulmonary disease: A randomized crossover trial Source: Annual Congress 2011 - COPD: integrated care and rehabilitation Year: 2011 Comprehensive care programme for patients with chronic obstructive pulmonary disease (COPD) --- A randomized controlled trial (RCT) Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2015